Nurse Practitioners, Physician Assistants, and Physicians Are Comparable in Managing the First Five Years of Diabetes

Yihan Yang, Yale School of Medicine
Qi Long, Emory University
Sandra L. Jackson, Emory University
Mary Rhee, Emory University
Anne Tomolo, Emory University
Darin Olson, Emory University
Lawrence S Phillips, Emory University

Journal Title: American Journal of Medicine
Volume: Volume 131, Number 3
Publisher: Elsevier: 12 months | 2018-03-01, Pages 276-+
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/j.amjmed.2017.08.026
Permanent URL: https://pid.emory.edu/ark:/25593/tnvxf

Final published version: http://dx.doi.org/10.1016/j.amjmed.2017.08.026

Copyright information:

© 2018
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Nurse practitioners, physician assistants, and physicians are comparable in managing the first five years of diabetes

Yihan Yang, MD1,2, Qi Long, PhD3, Sandra L. Jackson, MPH, PhD4,5, Mary K. Rhee, MD, MSCR5,6, Anne Tomolo, MD, MPH5,7, Darin Olson, MD, PhD5,6, and Lawrence S. Phillips, MD5,6

1Yale Internal Medicine Primary Care Residency Program, Yale School of Medicine, New Haven, CT
2Emory University School of Medicine, Atlanta, GA
3Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
4Nutrition and Health Sciences, Graduate Division of Biological and Biomedical Sciences, Emory University, Atlanta, GA
5Atlanta Veterans Affairs Medical Center, Decatur, GA
6Division of Endocrinology and Metabolism, Department of Medicine, Emory University School of Medicine, Atlanta, GA
7Division of General Medicine and Geriatrics, Department of Medicine, Emory University School of Medicine, Atlanta, GA

Abstract

Background—Increasing use of nurse practitioners (NPs) and physician assistants (PAs) is a possible solution to the shortage of primary care providers (PCPs) in the US, but the quality of care they provide is not well understood.
Methods—Since the scope of practice of the three provider types is similar in the Veterans Health Administration (VA), we determined whether patients managed by primary care NPs, PAs or physicians had similar HbA1c levels at comparable times in the natural history of diabetes. Our retrospective cohort study examined Veterans with diabetes newly-diagnosed in 2008, continuous primary care 2008–2012, and >75% of primary care visits with an NP, PA or physician.

Results—The 19,238 patients were 95.3% male, 77.7% white, and had mean age 68.5 years; 14.7%, 7.1%, and 78.2% of patients were managed by NPs, PAs and physicians, respectively. Median HbA1c was comparable at diagnosis (6.6%, 6.7%, 6.7%, p>0.05) and after 4 years (all 6.5%, p>0.5). HbA1c levels at initiation of the first (7.5–7.6%) and second (8.0–8.2%) oral medication for patients of NPs and PAs compared to that of physicians was also similar after adjusting for patient characteristics (all p>0.05). NPs started insulin at a lower HbA1c (9.4%) than physicians (9.7%), which remained significant after adjustment, p<0.05.

Conclusions—At diagnosis and during 4 years of follow-up, diabetes management by NPs and PAs was comparable to management by physicians. The VA model for roles of NPs and PAs may be broadly useful to help meet the demand for PCPs in the US.

Keywords
diabetes; midlevel providers; nurse practitioner; physician assistant; primary care

Introduction

Diabetes is a major health problem in the United States. More than 29 million Americans have diabetes, with 1.4 million newly-diagnosed in 2013\(^1\). In 2012, the American Diabetes Association (ADA) estimated that the total economic burden of diagnosed diabetes in the US was $176 billion in direct costs\(^2\).

After enactment of the Affordable Care Act (ACA), more Americans obtained access to health care. However, less than one third of physicians in the US currently practice in a primary care specialty\(^3\). One study estimated that the US requires an additional 46,000 primary care providers (PCPs) by 2025 in order to meet patient demands\(^4\). The shortfall in PCPs has spurred interest in the role of nurse practitioners (NPs) and physician assistants (PAs) in the primary care management of chronic diseases such as diabetes. While the cost of utilizing NPs and PAs is lower than physicians\(^5\), whether NPs, PAs and physicians deliver similar quality of care is poorly understood.

Several studies have suggested that patients managed by NPs and PAs have outcomes similar to those of physicians\(^6\–11\). However, due to scope of practice laws\(^3,12\), only a few studies included direct comparisons between NPs or PAs and physicians with similar independence and patient populations. Comparisons of diabetes care in particular have mainly been limited to cross-sectional analyses of single HbA1c levels without comparisons at similar time points in the natural history of the disease\(^9,13\).

We chose the Veterans Health Administration (VHA) as a model health care system in which to compare diabetes outcomes between patients managed by primary care NPs, PAs and physicians. Of the approximately 8.3 million patients seen at the VA each year\(^14\), an
estimated one in five has a diagnosis of diabetes\textsuperscript{15}. The VHA is the largest integrated health care system, as well as the largest employer of NPs and PAs in the nation\textsuperscript{16,17}. The majority of NPs and PAs in the VHA primary care setting are responsible for patient panels similar to those of physicians, and can prescribe non-controlled medications, place orders, and document without physician co-signatures\textsuperscript{18}. In 2010, up to 29\% of VHA primary care provider visits in 2010 were attended solely by NPs and PAs, with diabetes being the third most common primary care visit diagnosis for physicians and NPs, and fourth among PAs\textsuperscript{18}.

Our study utilized the national VHA Corporate Data Warehouse (CDW) database to compare NP, PA and physician management of patients with diabetes who were at comparable stages of their natural history – at diagnosis in 2008, during 4 years of follow-up, and at initiation of oral medications and insulin.

**METHODS**

**Study design**

We conducted a retrospective analysis to compare HbA1c levels in patients managed by primary care NPs, PAs or physicians. All patients were newly-diagnosed with diabetes in 2008, had four years of consistent primary care follow-up, and had annual HbA1c levels documented through 2012. This study was approved by the Emory University Institutional Review Board and the Atlanta VA Research and Development Committee.

**Database**

The CDW includes patient, visit, and provider information from all VHA encounters. Access to the CDW is obtained through the VA Informatics and Computing Infrastructure (VINCI).

**Patient selection**

“Primary care” was defined by use of the VHA database “clinic stop codes” for primary care/general medicine; women’s health; geriatric primary care; shared primary care; chronic infectious disease primary care; and spinal cord injury primary care.

We defined a patient as having newly-diagnosed diabetes in 2008 if he/she had at least one PCP visit per calendar year (CY) from 2006–2008 and met any one of the following validated criteria\textsuperscript{19,20} in 2008 but not in 2006–2007: (i) use of ICD-9 code 250.xx at a primary care visit, (ii) any use of 250.xx twice in 2008, and/or (iii) outpatient prescription of a diabetes drug. The diagnosis date was the earliest date in 2008 that the patient met one of the three criteria above. We further required patients to have at least one PCP visit in each year from 2006–2012 and within 6 months of diagnosis to ensure that patients had an adequate amount of contact with PCPs; at least one HbA1c measurement within 12 weeks before or 6 weeks after diagnosis; and at least one HbA1c per year from 2008–2012. Patients were categorized as managed by NPs, PAs or physicians if they had more than 50\% of PCP visits with one of the three provider types. A total of 19,238 patients were found to meet these criteria (Appendix Figure1).
Patient demographics / characteristics

Of the 19,238 patients selected, 17,288 (89.9%) had self-identified race data available. BMI was calculated at each visit for 16,727 patients who had height and weight information documented. A mean BMI value was calculated over time for each patient. Patients’ Charlson Comorbidity Index (CCI) scores were calculated using ICD-9 diagnosis codes as previously described\(^{21,22}\). We also identified whether patients had seen a diabetes specialist based upon visits to a diabetes clinic.

Medication Initiation

Initiation of oral antihyperglycemic medication or insulin was defined as the first outpatient prescription of medications with national drug codes HS502 (indicating oral agents) or HS501 (insulin agents), respectively, on or after the diagnosis date in 2008. Initiation of a second oral antihyperglycemic drug was determined as the issue date of a second HS502 drug of a different name. Inpatient prescriptions were not included.

HbA1c results

The HbA1c measurement closest to the diagnosis date and within 12 weeks before to 6 weeks after diagnosis was considered the HbA1c at diagnosis. Within each time period, values were averaged if patients had multiple tests. We also calculated a 5-year mean HbA1c of all levels reported from diagnosis in 2008 through four years of follow-up in 2012 for each patient. HbA1c at medication initiation utilized measurements within 12 weeks before to 6 weeks after prescription of the first oral antihyperglycemic medication, second oral medication, and/or insulin; approximately 98% of patients with diabetes medication prescriptions had HbA1c tested within this time frame.

Statistical Analysis

For group comparisons among different provider types, Chi-square tests were used for categorical variables; ANOVA and two-tailed t-tests to evaluate means of continuous variables; and Kruskal-Wallis and Wilcoxon tests to evaluate median values of outcomes which were not normally distributed. Statistical analysis of HbA1c outcomes is reported as both median and mean values due to right skewing of HbA1c distributions. Multivariate regression analyses were conducted for HbA1c outcomes to adjust for variations in patient characteristics. All statistical analyses were conducted using R and a p-value of <0.05 was considered statistically significant.

RESULTS

Diabetes cohort

In 2008, 19,238 veterans had two years of primary care before a new diagnosis of diabetes, continuity of primary care from 2006–2012, an HbA1c at diagnosis and at least one HbA1c per year from 2008–2012, and a majority of visits with a single provider type (Appendix Figure 1). Of these, 2,821 were managed by NPs, 1,367 by PAs, and 15,050 by physicians. Concordance between visit provider type and each patient’s designated managing provider type (i.e., for a patient managed by NPs by our criteria, the mean percent of primary care

*Am J Med*: Author manuscript; available in PMC 2019 March 01.
visits seen by an NP) was high at 82.3%, 78.9% and 92% for patients of NPs, PAs and physicians, respectively (Appendix Table 1). Patients managed by NPs and PAs had 14.5% and 15% of primary care visits with physicians, respectively.

Demographics

Patient characteristics are shown in Table 1. All values were clinically comparable although some were statistically different. NP patients were slightly older than physician patients (68.8 vs 68.4 years). NPs also managed a slightly lower percentage of male patients than physicians (94.3% vs. 95.5%). PAs had a higher percentage of white patients than physicians did (81.0% vs. 77.4%). NPs had patients with higher BMI compared to patients of physicians (32.6 vs. 32.2 kg/m$^2$). The patients of NPs, PAs and physicians had similar comorbidity, with median CCI scores of 0.0 in the two years prior to diabetes diagnosis, and CCI scores over the entire study period 2006–2012 of 1.0.

PAs had 4.8% of patients visit a diabetes specialist clinic, lower compared to the 7.0% of NP patients and 7.6% of physician patients (Figure 1). Neither NPs (80.2%) nor PAs (78.8%) had a significantly different percentage of patients prescribed any glucose-lowering medications compared to physicians (81.2%) (Figure 1). However, PAs had significantly fewer patients using insulin than physicians did (12.5% vs 14.6%).

HbA1c levels during the natural history of diabetes

Patients of NPs, PAs and physicians had similar median HbA1c levels both at diagnosis (6.6%, 6.7%, and 6.7%) (Figure 2) and after four years of primary care follow-up (all 6.5%). The median of each patient’s 5-year mean HbA1c (median 5-year mean HbA1c) from diagnosis in 2008 through 2012 for NPs was 6.4%, slightly lower than the median 5-year mean HbA1c of 6.5% for patients of physicians. The median 5-year mean HbA1c level for patients of PAs was not different compared to NPs or physicians.

A total of 15,841 patients were prescribed glucose-lowering medications. Of these, 15,301 (96%) had at least one oral medication, 5,889 (37%) at least two oral medications, and 2,769 (17%) were prescribed insulin. Among these patients, 14,635 (96%) had an HbA1c level at initiation of the first oral drug; 5,271 at initiation of the second oral drug (89%); and 2,245 (81%) at initiation of insulin.

Median HbA1c at initiation of the first and second oral drug was significantly lower in patients of NPs (7.0% and 7.5%) compared to that of physicians (7.1% and 7.7%) (Figure 2), but NPs and physicians started patients on insulin at similar HbA1c levels (9.4% and 9.7%). There was no difference in median HbA1c levels at initiation of oral drugs or insulin between PAs and physicians.

Regression analysis showed that patient age was inversely associated with HbA1c level during the duration of the study, and during initiation of all diabetes medications. Being male and African American was independently associated with higher HbA1c throughout the duration of the study, and during initiation of all diabetes medications. After adjusting for these patient characteristics, the differences in HbA1c levels at initiation of the first and second oral medications between NPs and physicians became non-significant (Table 2).
However, the difference in HbA1c levels at initiation of insulin between NPs and physicians remained significant (Table 2).

There was no difference in the median time from diabetes diagnosis to initiation of oral drugs or insulin between any of the three provider types (Appendix Table 2).

DISCUSSION

The results of our study demonstrate that primary care NPs and PAs provide glycemic management that is comparable to that of physicians for patients who had newly-diagnosed diabetes with four years of follow-up. There was no difference in HbA1c levels at diagnosis, initiation of the first and second oral medication, or after four years of primary care follow-up between NPs, PAs or physicians, after adjusting for patient characteristics. Patients of NPs were started on insulin at slightly lower HbA1c levels than patients of physicians after multivariate regression analyses. However, despite statistical significance, these differences in HbA1c were not clinically significant, much less than the 0.5% HbA1c difference that corresponds to an increased risk of developing diabetic retinopathy, as shown in the Diabetes Control and Complications Trial. The minimal differences in HbA1c outcomes are unlikely to be due to differences in patient complexity. Median Charlson Comorbidity Index scores within the two years prior to diagnosis, as well as throughout 2006–2012, were not significantly different between patients of NPs and physicians. NPs and physicians also had comparable percentages of patients with diabetes specialist visits and prescriptions for insulin. However, PAs had fewer patients with diabetes specialist visits, and fewer patients using insulin compared to physicians, suggesting that patients of PAs either were managed better with oral agents, or might have been less complex in terms of diabetes management.

The HbA1c trend of our patient population overall shows good control, with median HbA1c four years after diagnosis between 6.5 and 7%. This brings to question whether process measures within the VHA regarding diabetes management could explain some of our study findings. While the highly-integrated structure of VHA primary care differs from that in other primary care settings, especially in rural regions of the US, we are not aware of any particular algorithm followed systematically through the VHA that assigns a particular demographic of patients preferentially to PAs, NPs or physicians. Although the VHA has diabetes management guidelines, no specific algorithm is used uniformly across the health system. Although veterans tend to be older and to have more complex disease and comorbidities than the general US population, previous studies have shown that veterans tend to have better chronic disease outcomes than their non-veteran counterparts. The cost of care is also lower in the VHA compared to non-VA settings. Further prospective, randomized, controlled trials would be helpful to determine the extent to which our findings will apply to other practice environments.

The results of our study are consistent with prior research comparing management of diabetes between NPs and physicians. Mundinger et al conducted a randomized trial in which urgent care and emergency room patients with diabetes who lacked a regular primary
care provider were assigned to NPs (n=58) or physicians (n=46) in four community-based primary care clinics in New York City\textsuperscript{9}. Six months after the first primary care visit, NPs and physicians had similar percentages of patients with insufficiently-controlled diabetes, and the groups had comparable HbA1cs of 9.5\% vs. 9.4\%. Jackson et al found that inclusion of NPs within a primary care practice was associated with patient HbA1c levels that were 0.3\% lower than in practices without NPs\textsuperscript{13}. Kuo et al conducted two retrospective studies of patients with diabetes cared for solely by primary care NPs or primary care physicians. Prevalence of patient comorbidities like heart disease, hypertension, metabolic disorders were similar between the two patient groups. They found that HbA1c levels and preventable diabetes-related hospitalizations were comparable between the two provider groups\textsuperscript{27}, and adjusted Medicare spending per patient between the two provider groups was similar as well\textsuperscript{11}.

Processes of care have been found to be mixed when comparing management by NPs to that of physicians. Lenz et al\textsuperscript{28} found that NPs were more likely than physicians to document diabetes education, medication education, and urinalysis results, but not foot and cardiovascular examinations, glucose and creatinine levels, or ophthalmologist referrals. Ohman-Strickland et al\textsuperscript{29} found that family medicine practices that employed NPs were more likely to measure HbA1c, lipid, and urine microalbumin levels compared to practices without NPs, although the groups were comparable in percentage of patients with HbA1c <7.0\%. Kuo et al\textsuperscript{11} noted no significant difference in lipid screens and foot examinations, but significantly higher rates of eye examinations and vaccinations for patients cared for by NPs than physicians.

The strengths of our study include the incorporation of longitudinal data from medical centers across the nation, a large sample size, and a design which permitted comparison of HbA1c outcomes in patients who were at similar stages of their diabetes natural history and management. Our study also compared NPs, PAs and physicians who had similar prescribing privileges and scopes of practice. This allowed us to evaluate NPs and PAs who had levels of independence, responsibilities, and patient panels similar to those of their physician counterparts – a dimension which had been lacking in prior studies. While our operative definition of provider “ownership” as having greater than 50\% of primary care visits with either NPs, PAs or physicians could allow patients to receive some of their care from one of the other two provider types, “ownership” and visit provider type concordance was greater than 75\% for all groups.

Limitations to our study include its retrospective design, difference in sample size across provider groups, lack of female patients, and non-uniform testing of HbA1c. We do not know if NPs, PAs and physicians had similar allotted appointment time with patients. While most NPs and PAs in the VHA see patients without immediate, during-visit feedback from physicians on management, how frequent post-visit MD input is incorporated into diabetes management by NPs and PAs is not known. Additionally, while our evaluation was restricted to the year of diagnosis and the first four years of follow-up, management appeared to be comparable in the (delayed) initiation of insulin. It is possible that patients who received insulin at higher levels of HbA1c were diagnosed later in their natural history of disease.
Finally, the findings of comparable management of diabetes in our study may not be generalizable to management of other chronic disorders and to other care settings.

While glycemic control is one important aspect in the management of diabetes, this initial study did not address questions related to adverse effects of medications, or management of cardiovascular risk factors. While hypoglycemia is a common side effect of management, patient laboratory results would not necessarily be representative of the periodic episodes of mild to moderate hypoglycemia in outpatients which may or may not be reflected in the home blood glucose monitoring results, which patients bring to visits irregularly and are typically made by patient recall at visits. As a result, the true incidence of hypoglycemia is difficult to assess accurately, and was not included in this study. Further studies need to be conducted to compare diabetes care-specific process measures, blood pressure and hyperlipidemia management, and the incidence of diabetes-related complications such as microvascular end-organ damage, cardiovascular events, and hospitalizations among patients managed by NPs, PAs or physicians. Of equal importance is assessment of patient satisfaction among patients with diabetes managed by NPs and PAs vs. MDs.

From a health quality and policy standpoint, our results demonstrate that independently-practicing NPs and PAs, within a highly integrated health care system, are able to perform as well as physicians in management of diabetes at diagnosis and during 4 years of follow-up care. These findings indicate that there could be benefits from expanding the roles of NPs and PAs in patient management both within and outside of the VA – and that the VA model for use of NPs and PAs may be broadly useful to help meet the demand for primary care providers in the US.

Acknowledgments

All authors had access to the data and a role in writing the manuscript.

Funding Sources

Drs. Rhee, Phillips, Olson, and Tomolo are supported in part by the VA. This work is not intended to reflect the official opinion of the VA or the US government.

This work was supported in part by FDA award RO1FD003527 (L.S.P.), VA awards HSR&D IIR 07-138 (L.S.P., S.L.J.), and I01-CX001025 and I01-01BX003340 (L.S.P.), NIH awards R21DK099716 (L.S.P., Q.L., and S.L.J.), DK066204 (L.S.P.), U01 DK091958 (L.S.P. and M.K.R.), U01 DK098246 (L.S.P. and D.E.O.), R21 NS091630 (Q.L.), and a Cystic Fibrosis Foundation award PHILL112A0 (L.S.P.). The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors declare that there is potential duality of interest associated with this manuscript. With regard to potential conflicts of interest, within the past five years, Dr. Phillips has served on Scientific Advisory Boards for Boehringer Ingelheim, Profil and Janssen, and has or had research support from Merck, Amylin, Eli Lilly, Novo Nordisk, Sanofi, PhaseBio, Roche, Abbvie, Glaxo SmithKline, Janssen, Vascular Pharmaceuticals, Glaxo SmithKline, Astra Zeneca, and the Cystic Fibrosis Foundation. In the past, he was a speaker for Novartis and Merck, but not for the last five years. Darin E Olson has research support from Novo Nordisk and Amylin, and Qi Long receives support from NIH, PCORI, NSF, AHA, and the Cystic Fibrosis Foundation and served as a consultant for Eisai. Sandra Jackson received support from Amylin. These activities involve diabetes, but have nothing to do with this manuscript. After the study reported here was completed, Dr. Phillips founded a company, Diasyst Inc., which aims to develop and commercialize diabetes management programs.
References


Appendix

Appendix Figure 1. Consort diagram

51,116 veterans had two years of primary care before a new diagnosis of diabetes (diabetes diagnosis was defined by (i) use of ICD-9 code 250.xx at a primary care visit, (ii) any use of 250.xx twice in 2008, and/or (iii) outpatient prescription of a diabetes drug). Of these, 35,643 had continuity of primary care from 2006–2012 defined as at least one primary care attending visit per calendar year, and 19,601 also had an HbA1c at diagnosis and at least one A1c per year from 2008–2012. Less than 2% of patients (n=363) lacked a majority of visits with one particular provider type. Because such a small percentage of patients had “mixed”
provider type care, we included only the 19,238 patients who were managed either by NPs, PAs, or physicians. Of these, 2,821 were managed by NPs, 1,367 managed by PAs, and 15,050 managed by physicians. NP = nurse practitioner, PA = physician assistant, MD = physician (MD and DO).

**Appendix Table 1**

Managing provider and visit provider concordance for patients of NPs, PAs or physicians

<table>
<thead>
<tr>
<th>Patient managing provider type</th>
<th>NP</th>
<th>PA</th>
<th>Physician</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total primary care visits per patient, mean</td>
<td>19.6</td>
<td>19.7</td>
<td>19.4</td>
</tr>
<tr>
<td>Primary care visits with NPs, mean (%)</td>
<td>16.0 (82.3)</td>
<td>1.2 (6.1)</td>
<td>1.1 (5.3)</td>
</tr>
<tr>
<td>Primary care visits with PAs, mean (%)</td>
<td>0.6 (3.1)</td>
<td>15.4 (78.9)</td>
<td>0.6 (2.8)</td>
</tr>
<tr>
<td>Primary care visits with Physicians, mean (%)</td>
<td>3.0 (14.5)</td>
<td>3.1 (15.0)</td>
<td>17.7 (92)</td>
</tr>
</tbody>
</table>

Among patients designated as being managed by nurse practitioners (NPs), physician assistants (PAs) or physicians by our criteria, mean number and percent of total primary care visits (per patient) from 2006–2012 that were staffed by NPs, PAs or physicians.

**Appendix Table 2**

Median time in days from diagnosis to medication initiation in patients with newly-diagnosed diabetes managed by NPs, PAs or physicians

<table>
<thead>
<tr>
<th>Days from diagnosis to medication prescription, median, (25th, 75th percentiles)</th>
<th>NPs</th>
<th>PAs</th>
<th>Physicians</th>
<th>p value, group</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st oral Rx</td>
<td>0 (0, 8)</td>
<td>0 (0, 29)</td>
<td>0 (0, 28)</td>
<td>0.429</td>
</tr>
<tr>
<td>2nd oral Rx</td>
<td>556 (154, 1008)</td>
<td>640 (209, 1102)</td>
<td>560 (173, 1030)</td>
<td>0.134</td>
</tr>
<tr>
<td>insulin Rx</td>
<td>628 (4, 1177)</td>
<td>559 (1.25, 1117)</td>
<td>537 (1, 1123)</td>
<td>0.481</td>
</tr>
</tbody>
</table>

Time in days from diagnosis to initiation of diabetes medications in patients with newly-diagnosed diabetes who were managed by NPs, PAs or physicians. Median time to medication initiation was compared with Kruskal Wallis and Wilcoxon test.
 Highlights

- Primary care nurse practitioners, physician assistants, and physicians at the Veterans Health Administration care for diabetic patients with similar medical complexity.

- Patients managed by nurse practitioners, physician assistants, and physicians had comparable HbA1c at diagnosis (6.6–6.7%), initiation of first (7.5–7.6%) and second (8.0–8.2%) oral medications, initiation of insulin (9.4–9.7%), and after 4 years of follow-up (6.5).
Figure 1. Percent of patients prescribed diabetes medications, and referred to diabetes clinic, from 2008–2012 by managing provider type

Bar graphs depicting: percent of patients who completed at least one diabetes specialist clinic visit between 2008–2012; percent of patients who were prescribed any diabetes medication and/or insulin. DM = diabetes, Rx = prescription. Group P values shown were determined by Chi-square test.
Figure 2. Median HbA1c levels at systematic time points in the natural history of diabetes in patients newly-diagnosed in 2008

Box and whisker plots of median patient HbA1c levels compared between patients at various time points in the natural history of diabetes: 1) within 12 weeks before/6 weeks after diabetes diagnosis, 2) each patient’s mean HbA1c over 5 years from 2008–2012, 3) after four years of primary care follow-up in 2012, 4) at initiation of first oral antihyperglycemic medication, 5) at initiation of second oral antihyperglycemic medication, and 6) at initiation of insulin. Boxes include 25th–75th percentile, dashed lines indicate min-max range, dots represent outliers. Group P values shown were calculated using Kruskal-Wallis tests. Wilcoxon tests were used to compare HbA1c between two provider groups.
Demographics and characteristics of patients with newly-diagnosed diabetes in 2008, by managing provider type

<table>
<thead>
<tr>
<th></th>
<th>NPs</th>
<th>PAs</th>
<th>Physician</th>
<th>P-values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=2,821</td>
<td>n=1,367</td>
<td>n=15,050</td>
<td>ANOVA/KW</td>
</tr>
<tr>
<td><strong>Age at diagnosis</strong></td>
<td>68.8 ± 10.1</td>
<td>68.9 ± 10.0</td>
<td>68.4 ± 10.5</td>
<td>NP vs. Phys PA vs. Phys NP vs. PA</td>
</tr>
<tr>
<td></td>
<td>0.033</td>
<td>0.028</td>
<td>0.075</td>
<td>0.886</td>
</tr>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>2,659 (94.3)</td>
<td>1,313 (96.0)</td>
<td>14,367 (95.5)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Race Available</strong></td>
<td>2,495 (88.4)</td>
<td>1,197 (87.6)</td>
<td>13,596 (90.3)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>White (%)</strong></td>
<td>1,950 (78.2)</td>
<td>969 (81.0)</td>
<td>10,516 (77.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Black/African American (%)</strong></td>
<td>398 (16.0)</td>
<td>157 (13.1)</td>
<td>2,130 (15.8)</td>
<td>0.020</td>
</tr>
<tr>
<td><strong>Other (%)</strong></td>
<td>147 (5.9)</td>
<td>71 (5.9)</td>
<td>930 (6.8)</td>
<td></td>
</tr>
<tr>
<td><strong>BMI, mean kg/m² ± SD</strong></td>
<td>32.5 ± 5.7</td>
<td>32.2 ± 5.4</td>
<td>32.2 ± 5.6</td>
<td>0.014</td>
</tr>
<tr>
<td><strong>CCI 06–08, median (quartiles)</strong></td>
<td>0 (0,1)</td>
<td>0 (0,1)</td>
<td>0 (0,1)</td>
<td>0.271</td>
</tr>
<tr>
<td><strong>CCI 06–12, median (quartiles)</strong></td>
<td>1 (0,3)</td>
<td>1 (0,3)</td>
<td>1 (0,3)</td>
<td>0.066</td>
</tr>
</tbody>
</table>

Age at diagnosis, gender, race, body mass index, and Charlson Comorbidity Index scores for patients newly-diagnosed with diabetes in 2008, continuity of primary care from 2008 through 2012, and HbA1c levels recorded at diagnosis and at least once every calendar year from 2006–2012, who were managed mainly by NPs, PAs, or physicians. Race ratios and BMI means were calculated using total number of patients with race data and BMI data available. ANOVA and t-tests were used to compare means, Chi-square to compare percentages, Kruskal Wallis and Wilcoxon to compare medians. NP = nurse practitioner, PA = physician assistant, MD = physician (MD and DO), BMI = body mass index, CCI = Charlson Comorbidity Index.
Table 2

Multiple regression analyses of 5-year patient mean HbA1c, HbA1c at initiation of first oral medication, second oral medication, and insulin

<table>
<thead>
<tr>
<th></th>
<th>5-year mean 2008–2012</th>
<th>1st oral drug</th>
<th>2nd oral drug</th>
<th>Insulin</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>coefficient</td>
<td>p</td>
<td>coefficient</td>
<td>p</td>
</tr>
<tr>
<td><strong>Provider</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NP (ref=MD)</td>
<td>−0.028</td>
<td>0.46</td>
<td>−0.061</td>
<td>0.18</td>
</tr>
<tr>
<td>PA (ref=MD)</td>
<td>0.028</td>
<td>0.595</td>
<td>0.030</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>Age (years)</strong></td>
<td>−0.025</td>
<td>&lt;0.001</td>
<td>−0.023</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>CCI</strong></td>
<td>0.003</td>
<td>0.66</td>
<td>−0.009</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td>0.005</td>
<td>0.046</td>
<td>−0.001</td>
<td>0.88</td>
</tr>
<tr>
<td><strong>Male</strong></td>
<td>0.278</td>
<td>&lt;0.001</td>
<td>0.258</td>
<td>0.001</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black (ref=white)</td>
<td>0.618</td>
<td>&lt;0.001</td>
<td>0.485</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Other (ref=white)</td>
<td>0.115</td>
<td>0.03</td>
<td>0.176</td>
<td>0.006</td>
</tr>
<tr>
<td><strong>Diabetes clinic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes (ref=never)</td>
<td>0.723</td>
<td>&lt;0.001</td>
<td>0.736</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Multiple regression analyses of each patient’s 5-year mean HbA1c, HbA1c at initiation of first oral medication, second oral medication and insulin for patients with newly-diagnosed diabetes in 2008 and managed by primary care NPs, PAs or physicians. Coefficients indicate the change in HbA1c level associated with gender, race, diabetes clinic referral, age, Charlson Comorbidity Index and BMI. CCI = Charlson Comorbidity Index score calculated from visit diagnoses in 2008 through 2012, DM clinic = referral to diabetes clinic.